TC BioPharm Ltd ($TCBP) leads fight against Acute myeloid leukemia with its cell therapy product OmnImmune

November 22 06:04 2022
Scientific advances are creating new ways, previously only imaginable, to treat and prevent diseases.

Stocks were mixed Monday in a volatile session to start a short trading week due to the Thanksgiving holiday. Fears that China may again ramp up Covid restrictions after reporting deaths from the virus weighed on markets, sending energy stocks and oil prices lower. Traders also looked for further signals from the Federal Reserve about future interest rate hikes.

Some of the most active stocks on the street include Imago Biosciences Inc (NASDAQ:IMGO), ICU Medical Inc (NASDAQ:ICUI), Sotera Health Co (NASDAQ:SHC) and Meta Materials Inc (NASDAQ:MMAT). In addition, shares of Walt Disney Co (NYSE:DIS) rose more than 7% after the company announced that former CEO Bob Iger would return to the helm of the entertainment giant, replacing Bob Chapek immediately.

While the Dow rose to start short Thanksgiving week, one biotech company that we would like to draw your attention to is TC BioPharm Ltd (NASDAQ:TCBP). TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease.

Recently, TCBP received approval from the UK regulatory body MHRA to apply an 18-month extrapolated shelf life to its current allogeneic cell therapy product, OmnImmune®. This award enables TC BioPharm to ship and store sufficient product which can then be held cryopreserved at clinical sites to fulfill the requirements not only for its current Advanced Myeloid Leukemia trial ACHIEVE, but also for future clinical trials and eventually commercial treatment of patients. Additionally, TC BioPharm’s in-house quality control department will continue to gather data in order to extend the shelf-life of OmnImmune® (1)

TC BioPharm Ltd (NASDAQ:TCBP)’s platform technology allows Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Company’s pipeline includes OmnImmune, ImmuniStim and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product, being used for the treatment of acute myeloid leukemia (AML). ImmuniStim is an unmodified allogeneic gamma-delta T cell product, being used for the treatment of COVID-19. The Company also provides in-house and partner programs at the pre-clinical stage focused on developing CAR-modified allogeneic gamma delta T-cell products targeting solid and hematological indications.

TCBP recently announced that the company has completed its scientific advisory board (SAB) to advance new therapeutic trials and establish strategic relationships within the cell therapy sector (2)

“I appreciate the esteemed members of the SAB joining myself and TCBP in our efforts in building this innovative cell therapy development company,” said Bryan Kobel, Chief Executive Officer. “Cell therapy offers a myriad of opportunities in which to expand our gamma delta platform, and I believe that the breadth of expertise and knowledge represented on our SAB puts us in a unique position to connect with multiple companies across various disciplines in this space.”

“Current advancements within cell therapy represent an exciting leap forward in advancing our ability to understand and treat various blood cancers,” said Dr. Mark Bonyhadi, Scientific Advisory Board member at TC BioPharm. “I look forward to working with these strategic additions to our team as we advance our clinical trials and expand our strategic relationships.”

What sets TCBP apart from its competitors?

TCBP claims itself to be the Leading Gamma-Delta T-Cell Company. Vertically Integrated Operations, along with building exceptional teams and capabilities allows TC BioPharm to move quickly, providing unique ability to rapidly respond to internal discovery and external factors. GDTs provide a unique product development platform, which will enable next generation solid-tumor CAR-T and infectious disease therapies. Visit https://ir.tcbiopharm.com/ to learn more about this small cap biotech company.

Watch this Video To Learn More About TCBP and its product pipeline

Video Link: https://www.youtube.com/embed/uf-r6O9XRmg

Other companies in TC BioPharm (Holdings)’s space includes: Legend Biotech (NASDAQ:LEGN), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).

Source 1: https://ir.tcbiopharm.com/news/press-releases/detail/36/tc-biopharm-receives-mhra-approval-for-18-month

Source 2: https://ir.tcbiopharm.com/news/press-releases/detail/39/tc-biopharm-announces-key-additions-to-scientific-advisory

 

About InvestorBrandMedia.com – The team at InvestorBrandMedia has decades of strategy-driven, extensive media experience in helping navigate our clients through everchanging Digital Landscape. We specialize in a variety of marketing strategies that help promote our client visibility across multiple channels helping them expand the digital footprint in an ever-complex environment. InvestorBrandMedia.com specializes in ticker tagging services. Targeting the right audience is essential. Without effective distribution, a company’s message will fall on deaf ears or play to an empty room. Our growing distribution network consists of a diverse network of finance-focused blogs and websites, producing a robust mix of organic and cultivated interest. Let us help you jumpstart a rich following of qualified leads you can build on. Ticker Tagging is the process wherein your company is included with other sector related NASDAQ, NYSE, AMEX companies showcasing your news within a ticker tagged PR. The ticker tags are distributed to approximately 400 business and financial news portal including Benzinga, Yahoo, Google News, Digital journal and MarketWatch. Companies looking for IR/PR services can contact us directly at [email protected]

Disclaimer: InvestorBrandMedia is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are commercial advertisements and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available in this article is not intended to be, nor does it constitute investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report, and publication. In no event shall InvestorBrandMedia be liable to any member, guest, or third party for any damages of any kind arising out of the use of any content or other material published or made available by InvestorBrandMedia ., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. InvestorBrandMedia.com strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, Investor Brand Media, its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. As part of that content, readers, subscribers, and website viewers are expected to read the full disclaimers and financial disclosures statement that can be found on our website by visiting InvestorBrandMedia.com/Disclaimer. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. InvestorBrandMedia and its associate has been compensated one thousand two hundred and fifty dollars by a 3rd party for content, research, dissemination, and syndication pertaining to TCBP for 11/22/2022. We own zero shares of TCBP.

Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Email: [email protected]
Phone: 2019725655
Country: United States
Website: https://investorbrandmedia.com/